These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26382575)

  • 1. Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid.
    Hu M; Fok BS; Wo SK; Lee VH; Zuo Z; Tomlinson B
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):34-40. PubMed ID: 26382575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
    Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
    Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.
    Xiang X; Vakkilainen J; Backman JT; Neuvonen PJ; Niemi M
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1159-67. PubMed ID: 21655991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
    Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
    Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.
    Sissung TM; Huang PA; Hauke RJ; McCrea EM; Peer CJ; Barbier RH; Strope JD; Ley AM; Zhang M; Hong JA; Venzon D; Jackson JP; Brouwer KR; Grohar P; Glod J; Widemann BC; Heller T; Schrump DS; Figg WD
    Mol Pharmacol; 2019 Aug; 96(2):158-167. PubMed ID: 31175181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings.
    Xiang X; Backman JT; Neuvonen PJ; Niemi M
    Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):245-52. PubMed ID: 21902813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
    Campana G; Pasini P; Roda A; Spampinato S
    Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
    Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
    Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
    Fujita K; Iguchi Y; Une M; Watanabe S
    Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-fat diets enhance and delay ursodeoxycholic acid absorption but elevate circulating hydrophobic bile salts.
    Huang L; Wei W; Huang X; Li X; Liu H; Gui L; Jiang J; Wan L; Zhou X; Ding J; Jiang X; Zhang B; Lan K
    Front Pharmacol; 2023; 14():1168144. PubMed ID: 37138846
    [No Abstract]   [Full Text] [Related]  

  • 11. delta 22-Ursodeoxycholic acid, a unique metabolite of administered ursodeoxycholic acid in rats, indicating partial beta-oxidation as a major pathway for bile acid metabolism.
    Setchell KD; Yamashita H; Rodrigues CM; O'Connell NC; Kren BT; Steer CJ
    Biochemistry; 1995 Apr; 34(13):4169-78. PubMed ID: 7703228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation.
    Zhang Y; Jiang R; Zheng X; Lei S; Huang F; Xie G; Kwee S; Yu H; Farrar C; Sun B; Zhao A; Jia W
    Br J Pharmacol; 2019 Aug; 176(16):2848-2863. PubMed ID: 31077342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.
    Marzolini C; Tirona RG; Gervasini G; Poonkuzhali B; Assem M; Lee W; Leake BF; Schuetz JD; Schuetz EG; Kim RB
    Mol Endocrinol; 2007 Aug; 21(8):1769-80. PubMed ID: 17519356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor.
    Willart MA; van Nimwegen M; Grefhorst A; Hammad H; Moons L; Hoogsteden HC; Lambrecht BN; Kleinjan A
    Allergy; 2012 Dec; 67(12):1501-10. PubMed ID: 23004356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
    Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids.
    Erichsen TJ; Aehlen A; Ehmer U; Kalthoff S; Manns MP; Strassburg CP
    J Hepatol; 2010 Apr; 52(4):570-8. PubMed ID: 20189675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
    Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
    Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
    Yu DD; Andrali SS; Li H; Lin M; Huang W; Forman BM
    Bioorg Med Chem; 2016 Sep; 24(18):3986-3993. PubMed ID: 27372840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
    Beuers U; Trauner M; Jansen P; Poupon R
    J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing.
    Mroz MS; Lajczak NK; Goggins BJ; Keely S; Keely SJ
    Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G378-G387. PubMed ID: 29351391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.